Want to see ES:PHM full AI Analyst Report?
PHM Stock Chart & Stats
€79.30
-€0.40(-0.50%)
At close: 4:00 PM EDT
€79.30
-€0.40(-0.50%)
Day’s Range― - ―
52-Week Range€64.00 - €105.20
Previous CloseN/A
Volume3.54K
Average Volume (3M)74.16K
Market Cap
€1.39B
Enterprise Value€1.40K
Total Cash (Recent Filing)€167.85M
Total Debt (Recent Filing)€47.54M
Price to Earnings (P/E)16.9
Beta0.68
Next Earnings
Nov 04, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend Yield1.23%
Share Statistics
EPS (TTM)4.65
Shares Outstanding18,000,000
10 Day Avg. Volume71,270
30 Day Avg. Volume74,161
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.12
Price to Sales (P/S)5.82
P/FCF Ratio29.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€100.00Price Target Upside26.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.02
Revenue Forecast (FY)€205.75M
Bulls Say, Bears Say
Bulls Say
Very High Profit MarginsSustained high gross and net margins indicate durable pricing power and low incremental production costs for marketed oncology products. This margin profile supports scalable profitability, funds ongoing R&D and commercialization, and provides a buffer versus cyclical revenue swings over the next 2–6 months.
Conservative LeverageLow debt-to-equity and rising equity provide financial flexibility to fund clinical programs and commercial expansion without heavy reliance on external financing. This balance sheet strength reduces refinancing risk and preserves capacity to pursue partnerships or opportunistic M&A in the medium term.
Improved Free Cash FlowConsistent positive operating and free cash flow provides an internally generated funding source for development and commercialization, lowering dependency on dilutive financing. Strong FCF also supports milestone fulfillment and reinvestment into the pipeline over the coming months.
Bears Say
Historical Earnings VolatilityLarge swings in revenue and profitability driven by prior weak periods show the business is sensitive to product cycles and milestone timing. This structural variability complicates forecasting, raises the chance of short-term funding needs, and increases execution risk for ongoing programs.
Inconsistent Cash ConversionWhen earnings do not reliably convert to cash, working capital swings or timing of receipts can strain liquidity despite reported profits. This weak cash conversion can force external financing or delay investments if adverse events recur, weakening resilience to pipeline setbacks.
Revenue Dependent On Milestones/approvalsHeavy reliance on regulatory milestones and partner payments produces lumpy, binary revenue drivers. Structural dependence on successful trials and partner timing raises execution risk and could materially affect revenue and cash flow if key events are delayed or unfavorable.
Pharma Mar SA News
PHM FAQ
What was Pharma Mar SA’s price range in the past 12 months?
Pharma Mar SA lowest stock price was €64.00 and its highest was €105.20 in the past 12 months.
What is Pharma Mar SA’s market cap?
Pharma Mar SA’s market cap is €1.39B.
When is Pharma Mar SA’s upcoming earnings report date?
Pharma Mar SA’s upcoming earnings report date is Nov 04, 2026 which is in 97 days.
How were Pharma Mar SA’s earnings last quarter?
Pharma Mar SA released its earnings results on Jul 29, 2026. The company reported €0.16 earnings per share for the quarter, missing the consensus estimate of €0.178 by -€0.018.
Is Pharma Mar SA overvalued?
According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued.
Does Pharma Mar SA pay dividends?
Pharma Mar SA pays a Annually dividend of €1 which represents an annual dividend yield of 1.23%. See more information on Pharma Mar SA dividends here
What is Pharma Mar SA’s EPS estimate?
Pharma Mar SA’s EPS estimate is 0.19.
How many shares outstanding does Pharma Mar SA have?
Pharma Mar SA has 18,000,000 shares outstanding.
What happened to Pharma Mar SA’s price movement after its last earnings report?
Pharma Mar SA reported an EPS of €0.16 in its last earnings report, missing expectations of €0.178. Following the earnings report the stock price went up 3.185%.
Which hedge fund is a major shareholder of Pharma Mar SA?
Currently, no hedge funds are holding shares in ES:PHM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharma Mar SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€100.00 (26.10% Upside)
€100.00 (26.10% Upside)
Insider Transactions
Bought Shares
Worth $147.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.08%
12-Months-Change
Fundamentals
Return on Equity
1.23%
Trailing 12-Months
Asset Growth
23.22%
Trailing 12-Months
Company Description
Pharma Mar SA
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
PHM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong set of financial results and clear strategic progress—notably robust revenue growth (+27% y/y), a material improvement in profitability (EBITDA ~5x; net income +187%), healthy cash generation (EUR 53m) and multiple regulatory/commercial advances for Zepzelca and other assets. Pipeline momentum (LAGOON, SaLuDo, PM54, PM534) and licensing deals (e.g., Merck for Japan) provide additional upside. Offsetting factors include a 12% decline in U.S. Zepzelca royalties driven by FX and competition, outstanding pricing/reimbursement negotiations in Europe, exposure to partner-controlled disclosures, generics risk for Yondelis, and planned increases in commercial spending. Overall, positive operational and financial trends materially outweigh the identified risks, though execution on European launches and partner dynamics will be key to sustaining momentum.View all ES:PHM earnings summariesPHM Stock 12 Month Forecast
Average Price Target
€100.00
▲(26.10% Upside)
Technical Analysis
Laboratorios Farmaceuticos Rovi
―
Oryzon Genomics SA
―
―
1nKemia IUCT Group SA
―
Atrys Health SA
―